{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:33:54Z","timestamp":1793115234027,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Catania","id":[{"id":"https:\/\/ror.org\/03a64bh57","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle associated with an increased risk of atherosclerotic cardiovascular disease (ASCVD), including coronary artery disease, ischemic stroke, peripheral artery disease, and calcific aortic valve stenosis. Structurally, Lp(a) consists of an LDL-like particle covalently bound to apolipoprotein(a), a plasminogen-like glycoprotein that confers distinct biological properties. In particular, Lp(a) is the main circulating carrier of oxidized phospholipids, which promote endothelial dysfunction and vascular inflammation. Lp(a) contributes to vascular injury through multiple mechanisms, including lipid retention within the arterial wall, inflammatory activation, impairment of fibrinolysis, and vascular calcification. These processes contribute to plaque development and progression. Circulating Lp(a) levels are largely determined by genetic variability within the\n                    <jats:italic>LPA<\/jats:italic>\n                    gene, particularly by kringle IV type 2 copy number variation, which influences apolipoprotein(a) isoform size and secretion. Despite its clinical relevance, therapeutic options specifically targeting Lp(a) remain limited. Lipoprotein apheresis is the main available strategy for a substantial reduction in selected high-risk patients, while conventional lipid-lowering therapies have minimal effects and PCSK9 inhibitors provide only partial reductions. However, several targeted therapies are currently under investigation. Antisense oligonucleotides and small interfering RNAs reduce hepatic\n                    <jats:italic>LPA<\/jats:italic>\n                    expression and achieve marked reductions in circulating Lp(a) levels, and novel small molecule agents interfere with Lp(a) particle formation. Gene-editing strategies are a potential future approach for long-term Lp(a) reduction. In conclusion, Lp(a) is a key determinant of residual cardiovascular risk. A better understanding of its pathophysiology and the development of targeted therapies may improve cardiovascular risk stratification and prevention strategies.\n                  <\/jats:p>","DOI":"10.1007\/s11739-026-04492-x","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:40:32Z","timestamp":1786340432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipoprotein(a): from the complex metabolism to the optimal lowering drug"],"prefix":"10.1007","author":[{"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Berteotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giosiana","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Cosco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Di Pino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Alfano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7023-3649","authenticated-orcid":false,"given":"Roberto","family":"Scicali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"4492_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","volume":"71","author":"EA Enas","year":"2019","unstructured":"Enas EA, Varkey B, Dharmarajan TS et al (2019) Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction. Indian Heart J 71:99\u2013112. https:\/\/doi.org\/10.1016\/j.ihj.2019.03.004","journal-title":"Indian Heart J"},{"key":"4492_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-025-00760-1","volume":"19","author":"S Doherty","year":"2025","unstructured":"Doherty S, Hernandez S, Rikhi R et al (2025) Lipoprotein(a) as a causal risk factor for cardiovascular disease. Curr Cardiovasc Risk Rep 19:8. https:\/\/doi.org\/10.1007\/s12170-025-00760-1","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"4492_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.103845","volume":"35","author":"M Averna","year":"2025","unstructured":"Averna M, Cefal\u00f9 AB (2025) LP(a): the new marker of high cardiovascular risk. Nutr Metab Cardiovasc Dis 35:103845. https:\/\/doi.org\/10.1016\/j.numecd.2024.103845","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"4492_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S, Ference BA, Staley JR et al (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies. JAMA Cardiol 3:619. https:\/\/doi.org\/10.1001\/jamacardio.2018.1470","journal-title":"JAMA Cardiol"},{"key":"4492_CR5","doi-asserted-by":"publisher","DOI":"10.1161\/ATV.0000000000000147","author":"G Reyes-Soffer","year":"2022","unstructured":"Reyes-Soffer G, Ginsberg HN, Berglund L et al (2022) Lipoprotein(a): a genetically determined causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. https:\/\/doi.org\/10.1161\/ATV.0000000000000147","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4492_CR6","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1042\/BCJ20240037","volume":"481","author":"MB Boffa","year":"2024","unstructured":"Boffa MB, Koschinsky ML (2024) Lipoprotein(a) and cardiovascular disease. Biochem J 481:1277\u20131296. https:\/\/doi.org\/10.1042\/BCJ20240037","journal-title":"Biochem J"},{"key":"4492_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/ATVBAHA.125.323880","volume":"46","author":"R Zubiran","year":"2026","unstructured":"Zubiran R, Remaley AT (2026) Lipoprotein(a) and the vascular redox interface: linking arteriosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 46:248\u2013250. https:\/\/doi.org\/10.1161\/ATVBAHA.125.323880","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4492_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/cells15040315","volume":"15","author":"HR Yun","year":"2026","unstructured":"Yun HR, Singh MK, Han S et al (2026) Lipoprotein(a) and cardiovascular disease: from genetic risk factor to therapeutic target. Cells 15:315. https:\/\/doi.org\/10.3390\/cells15040315","journal-title":"Cells"},{"key":"4492_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.arteri.2026.500892","author":"F Di Giacomo Barbagallo","year":"2026","unstructured":"Di Giacomo Barbagallo F, Gonz\u00e1lez-Lle\u00f3 A, Amigo N et al (2026) Prevalence of elevated lipoprotein(a) levels and associated atherosclerotic cardiovascular diseases in subjects with metabolic disorders: a real-world study in a lipid unit. Clin Investig Arterioscler. https:\/\/doi.org\/10.1016\/j.arteri.2026.500892","journal-title":"Clin Investig Arterioscler"},{"key":"4492_CR10","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J 43:3925\u20133946. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"},{"key":"4492_CR11","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1194\/jlr.R067314","volume":"57","author":"K Schmidt","year":"2016","unstructured":"Schmidt K, Noureen A, Kronenberg F, Utermann G (2016) Structure, function, and genetics of lipoprotein (a). J Lipid Res 57:1339\u20131359. https:\/\/doi.org\/10.1194\/jlr.R067314","journal-title":"J Lipid Res"},{"key":"4492_CR12","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1074\/jbc.RA119.011251","volume":"295","author":"J Sandmark","year":"2020","unstructured":"Sandmark J, Tigerstr\u00f6m A, Akerud T et al (2020) Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain function. J Biol Chem 295:5136\u20135151. https:\/\/doi.org\/10.1074\/jbc.RA119.011251","journal-title":"J Biol Chem"},{"key":"4492_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","volume":"349","author":"S Coassin","year":"2022","unstructured":"Coassin S, Kronenberg F (2022) Lipoprotein(a) beyond the kringle IV repeat polymorphism: the complexity of genetic variation in the LPA gene. Atherosclerosis 349:17\u201335. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.003","journal-title":"Atherosclerosis"},{"key":"4492_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122196","volume":"10","author":"T Brzoska","year":"2015","unstructured":"Brzoska T, Tanaka-Murakami A, Suzuki Y et al (2015) Endogenously generated plasmin at the vascular wall injury site amplifies lysine binding site-dependent plasminogen accumulation in microthrombi. PLoS ONE 10:e0122196. https:\/\/doi.org\/10.1371\/journal.pone.0122196","journal-title":"PLoS ONE"},{"key":"4492_CR15","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","volume":"49","author":"C Bergmark","year":"2008","unstructured":"Bergmark C, Dewan A, Orsoni A et al (2008) A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 49:2230\u20132239. https:\/\/doi.org\/10.1194\/jlr.M800174-JLR200","journal-title":"J Lipid Res"},{"key":"4492_CR16","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","volume":"349","author":"B Enkhmaa","year":"2022","unstructured":"Enkhmaa B, Berglund L (2022) Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis 349:53\u201362. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.006","journal-title":"Atherosclerosis"},{"key":"4492_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813886","volume":"24","author":"F Fogacci","year":"2023","unstructured":"Fogacci F, Di Micoli V, Avagimyan A et al (2023) Assessment of apolipoprotein(a) isoform size using phenotypic and genotypic methods. Int J Mol Sci 24:13886. https:\/\/doi.org\/10.3390\/ijms241813886","journal-title":"Int J Mol Sci"},{"key":"4492_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jacc.2023.10.039","volume":"83","author":"E Bj\u00f6rnson","year":"2024","unstructured":"Bj\u00f6rnson E, Adiels M, Taskinen M-R et al (2024) Lipoprotein(a) is markedly more atherogenic than LDL. J Am Coll Cardiol 83:385\u2013395. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.039","journal-title":"J Am Coll Cardiol"},{"key":"4492_CR19","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s11739-020-02276-5","volume":"15","author":"A Sereni","year":"2020","unstructured":"Sereni A, Sticchi E, Gori AM et al (2020) Genetic and nutritional factors determining circulating levels of lipoprotein(a): results of the \u201cmontignoso study.\u201d Intern Emerg Med 15:1239\u20131245. https:\/\/doi.org\/10.1007\/s11739-020-02276-5","journal-title":"Intern Emerg Med"},{"key":"4492_CR20","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","volume":"38","author":"S Coassin","year":"2017","unstructured":"Coassin S, Erhart G, Weissensteiner H et al (2017) A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction. Eur Heart J 38:1823\u20131831. https:\/\/doi.org\/10.1093\/eurheartj\/ehx174","journal-title":"Eur Heart J"},{"key":"4492_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","volume":"349","author":"BJ Arsenault","year":"2022","unstructured":"Arsenault BJ, Kamstrup PR (2022) Lipoprotein(a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis 349:7\u201316. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.015","journal-title":"Atherosclerosis"},{"key":"4492_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/ATVBAHA.121.317335","volume":"42","author":"A Youssef","year":"2022","unstructured":"Youssef A, Clark JR, Marcovina SM et al (2022) Apo(a) and ApoB interact noncovalently within hepatocytes: implications for regulation of Lp(a) levels by modulation of ApoB secretion. Arterioscler Thromb Vasc Biol 42:289\u2013304. https:\/\/doi.org\/10.1161\/ATVBAHA.121.317335","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4492_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24010170","volume":"24","author":"A Maloberti","year":"2022","unstructured":"Maloberti A, Fabbri S, Colombo V et al (2022) Lipoprotein(a): cardiovascular disease, aortic stenosis and new therapeutic option. Int J Mol Sci 24:170. https:\/\/doi.org\/10.3390\/ijms24010170","journal-title":"Int J Mol Sci"},{"key":"4492_CR24","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.atherosclerosis.2022.04.002","volume":"349","author":"K Chemello","year":"2022","unstructured":"Chemello K, Chan DC, Lambert G, Watts GF (2022) Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis 349:82\u201391. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.002","journal-title":"Atherosclerosis"},{"key":"4492_CR25","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1194\/jlr.RA120001023","volume":"61","author":"A Santonastaso","year":"2020","unstructured":"Santonastaso A, Maggi M, De Jonge H, Scotti C (2020) High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site. J Lipid Res 61:1687\u20131696. https:\/\/doi.org\/10.1194\/jlr.RA120001023","journal-title":"J Lipid Res"},{"key":"4492_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2023.100336","volume":"64","author":"A Matveyenko","year":"2023","unstructured":"Matveyenko A, Matienzo N, Ginsberg H et al (2023) Relationship of apolipoprotein(a) isoform size with clearance and production of lipoprotein(a) in a diverse cohort. J Lipid Res 64:100336. https:\/\/doi.org\/10.1016\/j.jlr.2023.100336","journal-title":"J Lipid Res"},{"key":"4492_CR27","doi-asserted-by":"publisher","DOI":"10.5935\/abc.20140101","author":"RC Maranh\u00e3o","year":"2014","unstructured":"Maranh\u00e3o RC, Carvalho PO, Strunz CC, Pileggi F (2014) Lipoprotein (a): structure, pathophysiology and clinical implications. Arq Bras Cardiol. https:\/\/doi.org\/10.5935\/abc.20140101","journal-title":"Arq Bras Cardiol"},{"key":"4492_CR28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.69824","author":"M Sinha","year":"2024","unstructured":"Sinha M, Maged R, Tarar P et al (2024) Efficacy of traditional anti-lipidemic drugs in lowering lipoprotein(a) levels: a systematic review. Cureus. https:\/\/doi.org\/10.7759\/cureus.69824","journal-title":"Cureus"},{"key":"4492_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07432-z","volume":"23","author":"G Bosco","year":"2025","unstructured":"Bosco G, Di Giacomo Barbagallo F, Di Marco M et al (2025) Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. J Transl Med 23:1371. https:\/\/doi.org\/10.1186\/s12967-025-07432-z","journal-title":"J Transl Med"},{"key":"4492_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3390\/diseases11040145","volume":"11","author":"OI Afanasieva","year":"2023","unstructured":"Afanasieva OI, Tyurina AV, Ezhov MV et al (2023) Lipoprotein(a) and low-molecular-weight apo(a) phenotype as determinants of new cardiovascular events in patients with premature coronary heart disease. Diseases 11:145. https:\/\/doi.org\/10.3390\/diseases11040145","journal-title":"Diseases"},{"key":"4492_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.16469","volume":"27","author":"AC Razavi","year":"2025","unstructured":"Razavi AC, Bhatia HS, Blumenthal RS et al (2025) Why, how and in whom should we measure levels of lipoprotein(a): a review of the latest evidence and clinical implications. Diabetes Obes Metab 27:34\u201346. https:\/\/doi.org\/10.1111\/dom.16469","journal-title":"Diabetes Obes Metab"},{"key":"4492_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20186721","volume":"20","author":"P Vinci","year":"2023","unstructured":"Vinci P, Di Girolamo FG, Panizon E et al (2023) Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health 20:6721. https:\/\/doi.org\/10.3390\/ijerph20186721","journal-title":"Int J Environ Res Public Health"},{"key":"4492_CR33","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","volume":"41","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Chapman MJ, Krauss RM et al (2020) Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European atherosclerosis society consensus panel. Eur Heart J 41:2313\u20132330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962","journal-title":"Eur Heart J"},{"key":"4492_CR34","doi-asserted-by":"publisher","first-page":"361","DOI":"10.11613\/BM.2025.030503","volume":"35","author":"J Jeras","year":"2025","unstructured":"Jeras J, \u0160ebe\u0161tjen M, Zupan J, Ugov\u0161ek S (2025) Influence of LDL cholesterol and Lp(a) on monocytes and macrophages in atherosclerosis. Biochem Med (Zagreb) 35:361\u2013374. https:\/\/doi.org\/10.11613\/BM.2025.030503","journal-title":"Biochem Med (Zagreb)"},{"key":"4492_CR35","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1161\/CIRCULATIONAHA.125.073855","volume":"152","author":"S Tsimikas","year":"2025","unstructured":"Tsimikas S, Szarek M, Cobbaert CM et al (2025) Oxidized phospholipids, lipoprotein(a), and cardiovascular outcomes after acute coronary syndrome. Circulation 152:1666\u20131678. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.073855","journal-title":"Circulation"},{"key":"4492_CR36","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.trsl.2008.12.005","volume":"153","author":"P Fu","year":"2009","unstructured":"Fu P, Birukov KG (2009) Oxidized phospholipids in control of inflammation and endothelial barrier. Transl Res 153:166\u2013176. https:\/\/doi.org\/10.1016\/j.trsl.2008.12.005","journal-title":"Transl Res"},{"key":"4492_CR37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11883-024-01215-5","volume":"26","author":"T Qin","year":"2024","unstructured":"Qin T, Ma T-Y, Huang K et al (2024) Lipoprotein (a)-related inflammatory imbalance: a novel horizon for the development of atherosclerosis. Curr Atheroscler Rep 26:383\u2013394. https:\/\/doi.org\/10.1007\/s11883-024-01215-5","journal-title":"Curr Atheroscler Rep"},{"key":"4492_CR38","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","volume":"126","author":"JG Schnitzler","year":"2020","unstructured":"Schnitzler JG, Hoogeveen RM, Ali L et al (2020) Atherogenic lipoprotein(a) increases vascular glycolysis, thereby facilitating inflammation and leukocyte extravasation. Circ Res 126:1346\u20131359. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.316206","journal-title":"Circ Res"},{"key":"4492_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00060","author":"D El Kebir","year":"2013","unstructured":"El Kebir D, Filep JG (2013) Modulation of neutrophil apoptosis and the resolution of inflammation through \u03b22 integrins. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2013.00060","journal-title":"Front Immunol"},{"key":"4492_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.785220","author":"L Farahi","year":"2021","unstructured":"Farahi L, Sinha SK, Lusis AJ (2021) Roles of macrophages in atherogenesis. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2021.785220","journal-title":"Front Pharmacol"},{"key":"4492_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","volume":"16","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Koschinsky ML (2019) Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. Nat Rev Cardiol 16:305\u2013318. https:\/\/doi.org\/10.1038\/s41569-018-0153-2","journal-title":"Nat Rev Cardiol"},{"key":"4492_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1705738","author":"D Li","year":"2026","unstructured":"Li D, Qian Y, Wan L et al (2026) Lipoprotein-associated phospholipase A2 (Lp-PLA2): a key hub linking lipid metabolism and immune inflammation. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2026.1705738","journal-title":"Front Immunol"},{"key":"4492_CR43","doi-asserted-by":"publisher","DOI":"10.15420\/ecr.2025.66","author":"A Filtz","year":"2026","unstructured":"Filtz A, Slipczuk L, Gulati M (2026) Presumed mechanisms underlying lipoprotein(a)-caused atherosclerosis. Eur Cardiol Rev. https:\/\/doi.org\/10.15420\/ecr.2025.66","journal-title":"Eur Cardiol Rev"},{"key":"4492_CR44","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/VHRM.S555127","volume":"21","author":"B Mwipatayi","year":"2025","unstructured":"Mwipatayi B, Dodd J, Ahmad Bazlee AH et al (2025) Lipoprotein(a) and its role in peripheral arterial disease: a narrative review. Vasc Health Risk Manag 21:965\u2013981. https:\/\/doi.org\/10.2147\/VHRM.S555127","journal-title":"Vasc Health Risk Manag"},{"key":"4492_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1610395","author":"P Wambua","year":"2025","unstructured":"Wambua P, Wahinya M, Khan Z (2025) The role of elevated lipoprotein(a) in aortic valve disease: a systematic review. Front Cardiovasc Med. https:\/\/doi.org\/10.3389\/fcvm.2025.1610395","journal-title":"Front Cardiovasc Med"},{"key":"4492_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11739-018-1925-8","volume":"14","author":"E Sticchi","year":"2019","unstructured":"Sticchi E, Giusti B, Cordisco A et al (2019) Role of lipoprotein (a) and LPA KIV2 repeat polymorphism in bicuspid aortic valve stenosis and calcification: a proof of concept study. Intern Emerg Med 14:45\u201350. https:\/\/doi.org\/10.1007\/s11739-018-1925-8","journal-title":"Intern Emerg Med"},{"key":"4492_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2024.101543","volume":"55","author":"MI Khan","year":"2024","unstructured":"Khan MI, Zahir RS, Dominguez AC, Romeo FJ (2024) Role of lipoprotein (A) in aortic valve stenosis: novel disease mechanisms and emerging pharmacotherapeutic approaches. IJC Heart Vasc 55:101543. https:\/\/doi.org\/10.1016\/j.ijcha.2024.101543","journal-title":"IJC Heart Vasc"},{"key":"4492_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001423","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M et al (2026) 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000001423","journal-title":"Circulation"},{"key":"4492_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac361","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European atherosclerosis society consensus statement. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361","journal-title":"Eur Heart J"},{"key":"4492_CR50","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","volume":"46","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, van LennepRoeters JE et al (2025) 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J 46:4359\u20134378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190","journal-title":"Eur Heart J"},{"key":"4492_CR51","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11789-017-0087-y","volume":"12","author":"F van Buuren","year":"2017","unstructured":"van Buuren F, Horstkotte D, Knabbe C et al (2017) Incidence of elevated lipoprotein (a) levels in a large cohort of patients with cardiovascular disease. Clin Res Cardiol Suppl 12:55\u201359. https:\/\/doi.org\/10.1007\/s11789-017-0087-y","journal-title":"Clin Res Cardiol Suppl"},{"key":"4492_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-024-01252-0","volume":"27","author":"K Anchouche","year":"2025","unstructured":"Anchouche K, Thanassoulis G (2025) Lp(a): a rapidly evolving therapeutic landscape. Curr Atheroscler Rep 27:7. https:\/\/doi.org\/10.1007\/s11883-024-01252-0","journal-title":"Curr Atheroscler Rep"},{"key":"4492_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.120420","volume":"408","author":"S Xie","year":"2025","unstructured":"Xie S, Galimberti F, Olmastroni E et al (2025) Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials. Atherosclerosis 408:120420. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120420","journal-title":"Atherosclerosis"},{"key":"4492_CR54","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag089","author":"B Razi","year":"2026","unstructured":"Razi B, Eslami M, Aslani S et al (2026) The impact of lipid apheresis on changes of lipoprotein(a): a systematic review and meta-analysis. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwag089","journal-title":"Eur J Prev Cardiol"},{"key":"4492_CR55","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP et al (2019) Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139:1483\u20131492. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184","journal-title":"Circulation"},{"key":"4492_CR56","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA, Szarek M, Aylward PE et al (2020) Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 75:133\u2013144. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057","journal-title":"J Am Coll Cardiol"},{"key":"4492_CR57","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M et al (2025) Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med 393:51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2415820","journal-title":"N Engl J Med"},{"key":"4492_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s12170-025-00759-8","volume":"19","author":"C De Los Reyes","year":"2025","unstructured":"De Los Reyes C, Rikhi RR, Doherty S et al (2025) Current clinical trials for treating elevated lipoprotein(a). Curr Cardiovasc Risk Rep 19:7. https:\/\/doi.org\/10.1007\/s12170-025-00759-8","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"4492_CR59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.124.069210","volume":"151","author":"A Greco","year":"2025","unstructured":"Greco A, Finocchiaro S, Spagnolo M et al (2025) Lipoprotein(a) as a pharmacological target: premises, promises, and prospects. Circulation 151:400\u2013415. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.069210","journal-title":"Circulation"},{"key":"4492_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382:244\u2013255. https:\/\/doi.org\/10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"key":"4492_CR61","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B et al (2022) Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med 387:1855\u20131864. https:\/\/doi.org\/10.1056\/NEJMoa2211023","journal-title":"N Engl J Med"},{"key":"4492_CR62","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X et al (2023) Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a). JAMA 330:2075. https:\/\/doi.org\/10.1001\/jama.2023.21835","journal-title":"JAMA"},{"key":"4492_CR63","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1001\/jama.2024.4504","volume":"331","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wolski K, Watts GF et al (2024) Single ascending and multiple-dose trial of zerlasiran, a short interfering RNA targeting lipoprotein(a). JAMA 331:1534. https:\/\/doi.org\/10.1001\/jama.2024.4504","journal-title":"JAMA"},{"key":"4492_CR64","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","volume":"333","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Ni W, Rhodes GM et al (2025) Oral muvalaplin for lowering of lipoprotein(a). JAMA 333:222. https:\/\/doi.org\/10.1001\/jama.2024.24017","journal-title":"JAMA"},{"key":"4492_CR65","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3390\/ph18050753","volume":"18","author":"N Katsiki","year":"2025","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I (2025) Lp(a)-lowering agents in development: a new era in tackling the burden of cardiovascular risk? Pharmaceuticals (Basel) 18:753. https:\/\/doi.org\/10.3390\/ph18050753","journal-title":"Pharmaceuticals (Basel)"},{"key":"4492_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","volume":"287","author":"L Cho","year":"2025","unstructured":"Cho L, Nicholls SJ, Nordestgaard BG et al (2025) Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a). Am Heart J 287:1\u20139. https:\/\/doi.org\/10.1016\/j.ahj.2025.03.019","journal-title":"Am Heart J"},{"key":"4492_CR67","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","volume":"392","author":"SE Nissen","year":"2025","unstructured":"Nissen SE, Ni W, Shen X et al (2025) Lepodisiran \u2014 a long-duration small interfering RNA targeting lipoprotein(a). N Engl J Med 392:1673\u20131683. https:\/\/doi.org\/10.1056\/NEJMoa2415818","journal-title":"N Engl J Med"},{"key":"4492_CR68","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1056\/NEJMe2503824","volume":"392","author":"DJ Rader","year":"2025","unstructured":"Rader DJ (2025) Targeting lipoprotein(a) \u2014 the next frontier in cardiovascular disease. N Engl J Med 392:1740\u20131742. https:\/\/doi.org\/10.1056\/NEJMe2503824","journal-title":"N Engl J Med"},{"key":"4492_CR69","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jama.2024.21957","volume":"332","author":"SE Nissen","year":"2024","unstructured":"Nissen SE, Wang Q, Nicholls SJ et al (2024) Zerlasiran\u2014a small-interfering RNA targeting lipoprotein(a). JAMA 332:1992. https:\/\/doi.org\/10.1001\/jama.2024.21957","journal-title":"JAMA"},{"key":"4492_CR70","doi-asserted-by":"publisher","first-page":"202","DOI":"10.4244\/EIJ-D-25-00598","volume":"22","author":"A Oshima","year":"2026","unstructured":"Oshima A, Serruys PW, Garg S et al (2026) Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation. EuroIntervention 22:202\u2013223. https:\/\/doi.org\/10.4244\/EIJ-D-25-00598","journal-title":"EuroIntervention"},{"key":"4492_CR71","doi-asserted-by":"publisher","DOI":"10.5114\/aoms\/212635","author":"T Saniewski","year":"2025","unstructured":"Saniewski T, Zimodro JM, Procyk G et al (2025) Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC\/EAS guidelines. Arch Med Sci. https:\/\/doi.org\/10.5114\/aoms\/212635","journal-title":"Arch Med Sci"},{"key":"4492_CR72","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","volume":"404","author":"BG Nordestgaard","year":"2024","unstructured":"Nordestgaard BG, Langsted A (2024) Lipoprotein(a) and cardiovascular disease. Lancet 404:1255\u20131264. https:\/\/doi.org\/10.1016\/S0140-6736(24)01308-4","journal-title":"Lancet"},{"key":"4492_CR73","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehag092","author":"J Zhang","year":"2026","unstructured":"Zhang J, Navar AM, Tokgozoglu L (2026) Lipoprotein(a)-lowering therapies: a promising future. Eur Heart J. https:\/\/doi.org\/10.1093\/eurheartj\/ehag092","journal-title":"Eur Heart J"},{"key":"4492_CR74","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","volume":"578","author":"JA Doudna","year":"2020","unstructured":"Doudna JA (2020) The promise and challenge of therapeutic genome editing. Nature 578:229\u2013236. https:\/\/doi.org\/10.1038\/s41586-020-1978-5","journal-title":"Nature"},{"key":"4492_CR75","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyaf020","author":"L Wang","year":"2025","unstructured":"Wang L, Jiang F, Sun J et al (2025) Factorial Mendelian randomization of lipoprotein (a) lowering, low-density lipoprotein cholesterol lowering, and lifestyle improvements: joint associations with cardiovascular risk. Int J Epidemiol. https:\/\/doi.org\/10.1093\/ije\/dyaf020","journal-title":"Int J Epidemiol"},{"key":"4492_CR76","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.3390\/jcm15062179","volume":"15","author":"I Doma\u0144ski","year":"2026","unstructured":"Doma\u0144ski I, Kozie\u0142 A, Doma\u0144ski J, Trocha M (2026) Existing and potential therapeutic strategies for lowering lipoprotein(a) levels: an update. J Clin Med 15:2179. https:\/\/doi.org\/10.3390\/jcm15062179","journal-title":"J Clin Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04492-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04492-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:56:58Z","timestamp":1793113018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04492-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":76,"alternative-id":["4492"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04492-x","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this is a review article, no ethical approval was needed.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was not required for this study, as it is a review article and does not involve individual patient data.","order":3,"name":"Ethics","label":"Human and animal rights statement and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No artificial intelligence tool was used for data analysis, literature interpretation, or generation of scientific conclusions. Figures\u00a0\n                      \n                      and\n                      \n                      were created using BioRender. Figure\u00a0\n                      \n                      was prepared with graphical support from ChatGPT. All figures were critically reviewed and approved by the authors, who take full responsibility for the content of the manuscript and figures.","order":4,"name":"Ethics","label":"Artificial intelligence disclosure","group":{"name":"EthicsHeading","label":"Declarations"}}]}}